Send to

Choose Destination
Curr Drug Targets. 2017;18(15):1712-1721. doi: 10.2174/1389450117666160401120308.

Progress in Therapies for Myocardial Ischemia Reperfusion Injury.

Author information

Department of Cardiology, Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
Beijing Key Laboratory of Hypertension Research, Beijing, 100020, China.



Experimental studies of acute myocardial infarction have revealed that up to half of the final infarct size may be due to reperfusion injury rather than the initial ischemic incident. Research over the past three decades has deepened our understanding of the molecular mechanisms underlying ischemic reperfusion injury and several therapeutic strategies to decrease the incidence and severity of reperfusion injury have been explored.


To discuss the promising therapies and future perspectives on methods to attenuate myocardial reperfusion injury.


Existing therapies that address reperfusion can be divided into two major groups comprising nonpharmacological and pharmacological interventions. Myriad pharmacological and nonpharmacological approaches to reduce lethal reperfusion injury have been employed. Although many initial clinical studies were negative, more recent proof-of-concept clinical trials are promising. To date, the most encouraging results are with ischemic postconditioning, remote ischemic preconditioning, ANP, adenosine, cyclosporine and exenatide.


Studies demonstrate that nonpharmacological and pharmacological conditioning can be used together as part of a multifaceted approach to improve clinical outcomes in patients with ischemic heart disease.


Myocardial infarction; cardiac pharmacology; clinical trial; ischemic conditioning; myocardial reperfusion injury

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center